Literature DB >> 26413227

Central and peripheral testosterone effects in men with heart failure: An approach for cardiovascular research.

Željko Bušić1, Viktor Čulić1.   

Abstract

Heart failure (HF) is a syndrome recognized as a health problem worldwide. Despite advances in treatment, patients with HF still have increased morbidity and mortality. Testosterone is one of the most researched hormones in the course of HF. Growing interest regarding the effect of testosterone, on a variety of body systems, has increased the knowledge about its mechanisms of action. The terms central and peripheral effects are used to distinguish the effects of testosterone on cardiac and extracardiac structures. Central effects include influences on cardiomyocytes and electrophysiology. Peripheral effects include influences on blood vessels, baroreceptor reactivity, skeletal muscles and erythropoesis. Current knowledge about peripheral effects of testosterone may explain much about beneficiary effects in the pathophysiology of HF syndrome. However, central, i.e., cardiac effects of testosterone are to be further explored.

Entities:  

Keywords:  Cardiomyocytes; Electrophysiology; Exercise; Heart failure; Testosterone; Vasodilation

Year:  2015        PMID: 26413227      PMCID: PMC4577677          DOI: 10.4330/wjc.v7.i9.504

Source DB:  PubMed          Journal:  World J Cardiol


  71 in total

1.  Testosterone acts as a coronary vasodilator by a calcium antagonistic action.

Authors:  K M English; R D Jones; T H Jones; A H Morice; K S Channer
Journal:  J Endocrinol Invest       Date:  2002-05       Impact factor: 4.256

Review 2.  Testosterone and heart failure.

Authors:  Maurizio Volterrani; Giuseppe Rosano; Ferdinando Iellamo
Journal:  Endocrine       Date:  2012-06-24       Impact factor: 3.633

3.  Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.

Authors:  Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak
Journal:  Circulation       Date:  2006-06-05       Impact factor: 29.690

4.  Development of a ventilatory classification system in patients with heart failure.

Authors:  Ross Arena; Jonathan Myers; Joshua Abella; Mary Ann Peberdy; Daniel Bensimhon; Paul Chase; Marco Guazzi
Journal:  Circulation       Date:  2007-04-23       Impact factor: 29.690

Review 5.  Growth hormone: a newcomer in cardiovascular medicine.

Authors:  L Saccà
Journal:  Cardiovasc Res       Date:  1997-10       Impact factor: 10.787

6.  Estrogen and progestin use and the QT interval in postmenopausal women.

Authors:  Alan H Kadish; Philip Greenland; Marian C Limacher; William H Frishman; Sandra A Daugherty; Janice B Schwartz
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-10       Impact factor: 1.468

7.  Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone.

Authors:  T A M Karila; J E Karjalainen; M J Mäntysaari; M T Viitasalo; T A Seppälä
Journal:  Int J Sports Med       Date:  2003-07       Impact factor: 3.118

8.  Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: an in situ hybridization study.

Authors:  R B Simerly; C Chang; M Muramatsu; L W Swanson
Journal:  J Comp Neurol       Date:  1990-04-01       Impact factor: 3.215

9.  In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits.

Authors:  Xiao-Ke Liu; Alexander Katchman; Bernard H Whitfield; Grace Wan; Einsley M Janowski; Raymond L Woosley; Steven N Ebert
Journal:  Cardiovasc Res       Date:  2003-01       Impact factor: 10.787

10.  Orchiectomy or androgen receptor blockade attenuates baroreflex-mediated bradycardia in conscious rats.

Authors:  Gregg R Ward; Abdel A Abdel-Rahman
Journal:  BMC Pharmacol       Date:  2006-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.